Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay

Antiviral Research

Volumn 82, Issue 1, 2009, Pages 29-33

  Guo, Lizheng ^a   Garten, Rebecca J ^a   Foust, Angie S ^a   Sessions, Wendy M ^a   Okomo Adhiambo, Margaret ^a   Gubareva, Larisa V ^a   Klimov, Alexander I ^a   Xu, Xiyan ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

H274Y; Influenza A(H1N1) virus; Oseltamivir resistance; RT PCR RFLP

Indexed keywords

HISTIDINE; OSELTAMIVIR; TYROSINE; VIRUS RNA;

AMINO ACID SUBSTITUTION; AMPLICON; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CONTROL; GENETIC ENGINEERING; HEMISPHERE; INFLUENZA VIRUS A H1N1; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASON; SEN VIRUS; VIRUS CHARACTERIZATION; VIRUS IDENTIFICATION; VIRUS MUTATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL PROTEINS;

INFLUENZA A VIRUS;

EID: 62049085972     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.01.004     Document Type: Article

References (30)

1. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., and Klimov A.I. Incidence of adamantine resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
2. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. J. Am. Med. Assoc. 295 8 (2006) 891-894
3. Chutinimitkula S., Suwannakarna K., Chieochansina T., Maib L.Q., Damrongwatanapokinc S., Chaisinghc A., Amonsind A., Landte O., Songsermf T., Theamboonlersa A., and Poovorawana Y. H5N1 oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. J. Virol. Methods 139 (2007) 44-49
4. Colman P.M. Neuraminidase: enzyme and antigen. In: Krug R.M. (Ed). The Influenza Viruses (1989), Plenum Press, New York 175-210
5. De Jong M., Thanh T.T., Khanh T.H., Hien V.M., Smith G.J.D., Chau N.V., Cam B.V., Qui P.T., Ha D.Q., Guan Y., Peiris J.S.M., Hien T.T., and Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672
6. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., and Klimov A.I. Surveillance of resistance of adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196 (2007) 249-257
7. Deyde V.M., Okomo-Adhiambo M., Sheu T.G., Wallis T.R., Fry A., Dharan N., Klimov A.I., and Gubareva L.V. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81 1 (2008) 16-24
8. Duwe S., and Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 153 (2008) 134-141
9. European Center for Disease Prevention and Control, 2008. Emergence of seasonal influenza viruses type A/H1N1 with oseltamivir resistance in some European countries at the start of the 2007-8 influenza season. http://ecdc.europa.eu/pdf/080127_os.pdf.
10. Fazio D., Laufer A., Meek J., Palumbo J., Lynfield R., Morin C., Vick K., Baumbach J., Mueller M., Belflower R., Long C., and Kamimoto L. Influenza-testing and antiviral-agent prescribing practices-Connecticut, Minnesota, New Mexico, and New York, 2006-07 influenza season. Morb. Mortal. Wkly. Rep. 57 3 (2008) 61-65
11. Goodman, C., Mukherjee, D., Faulkner, E., 2006. How Effective Would Antiviral Vaccination and Antiviral Drug Prevention and Treatment Strategies be for Reducing the Impact of the Next Influenza Pandemic? WHO Regional Office for Europe, Copenhagen. Health Evidence Network report. http://www.euro.who.int/Document/E88034.pdf.
12. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., and Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183 (2001) 523-531
13. Gubareva L.V., Webster R.G., and Hayden F.G. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53 1 (2002) 47-61
14. Gubareva L.V. Molecular mechanism of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103 (2004) 199-203
15. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., and Zambon M.C. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eur. Surveill. 13 5 (2008) pii: 8026
16. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 (2003) 2264-2272
17. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006) 2395-2402
18. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N. Engl. J. Med. 353 (2005) 2633-2636
19. Mungall B.A., Xu X., and Klimov A. Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays. Avian Dis. 47 3 Suppl. (2003) 1141-1144
20. Mungall B.A., Xu X., and Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 103 (2004) 195-197
21. Nicoll A., Ciancio B., and Kramarz1 P. Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. Eur. Surveill. 13 5 (2008) pii: 8025
22. Schunemann H.J., Hill S.R., Kakad M., Bellamy R., Uyeki T.M., Hayden F.G., Yazdanpanah Y., Beigel J., Chotpitayasunondh T., Del Mar C., Farrar J., Tran T.H., Ozbay B., Sugaya N., Fukuda K., Shindo N., Stockman L., Vist G.E., Croisier A., Nagjdaliyev A., Roth C., Thomson G., Zucker H., Oxman A.D., and Rapid Advice Guideline Panel on Avian Influenza. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect. Dis. 7.1 (2007) 21-31
23. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R., Xu X., Bright R., Eboneé Butler E., Wallis T.R., Klimov A.I., and Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide in 2004-2008. Antimicrob. Agents Chemother. 52 9 (2008) 3284-3292
24. Smagala J.A., Dawson E.D., Mehlmann M., Townsend M.B., Kuchta R.D., and Rowlen K.L. ConFind: a robust tool for conserved sequence identification. Bioinformatics 21 (2005) 4420-4422
25. Ward P., Small I., Smith J., Suter P., and Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55 Suppl. 1 (2005) i5-i21
26. Weinstock D.M., Gubareva L.V., and Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 348 (2003) 867-868
27. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., and Hayden F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41 2 (2003) 742-750
28. World Health Organization, 2006. Rapid Advice Guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. http://www.who.int/csr/disease/avian_influenza/guidelines/pharmamanagement/en/index.html.
29. World Health Organization, 2008. Influenza A(H1N1) virus resistance to oseltamivir. http://www.who.int/csr/disease/influenza/h1n1_table/en/.
30. Zambon M., Hayden F.G., and the Global Neuraminidase Inhibitor Susceptibility Network. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49 (2001) 147-156